美国食品药品监督管理局顾问批准那他珠单抗用于治疗克罗恩病。 - Suppr

Suppr

超能文献

FDA advisers endorse natalizumab for Crohn's disease.

作者信息

Traynor Kate

出版信息

Am J Health Syst Pharm. 2007 Sep 15;64(18):1886, 1888, 1890. doi: 10.2146/news070080.

DOI:10.2146/news070080

PMID:17823090

Abstract

摘要

相似文献

FDA advisers endorse natalizumab for Crohn's disease.

Am J Health Syst Pharm. 2007 Sep 15;64(18):1886, 1888, 1890. doi: 10.2146/news070080.

The comeback kid: TYSABRI now FDA approved for Crohn disease.

J Clin Invest. 2008 Mar;118(3):825-6. doi: 10.1172/JCI35179.

Natalizumab (Tysabri) for Crohn's disease.

Med Lett Drugs Ther. 2008 May 5;50(1285):34-6.

Natalizumab for induction of remission in Crohn's disease.

Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.

Natalizumab for induction of remission in Crohn's disease.

Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.

TNF inhibitors for Crohn's disease: when, which, and for how long.

Med Lett Drugs Ther. 2013 Dec 23;55(1432):102-3.

Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.

Expert Opin Biol Ther. 2003 Sep;3(6):995-1000. doi: 10.1517/14712598.3.6.995.

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.

Inflamm Bowel Dis. 1998 Nov;4(4):328-9. doi: 10.1002/ibd.3780040415.

Natalizumab induction and maintenance therapy for Crohn's disease.

N Engl J Med. 2005 Nov 3;353(18):1912-25. doi: 10.1056/NEJMoa043335.

Natalizumab for active Crohn's disease.

N Engl J Med. 2003 Jan 2;348(1):24-32. doi: 10.1056/NEJMoa020732.

引用本文的文献

Vedolizumab: Beyond Inflammatory Bowel Disease.

Med Princ Pract. 2025 Jun 19:1-13. doi: 10.1159/000547015.

Targeting integrin pathways: mechanisms and advances in therapy.

Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6.

Monoclonal antibody treatments for multiple sclerosis.

Curr Treat Options Neurol. 2009 May;11(3):211-20. doi: 10.1007/s11940-009-0025-5.

Monoclonal antibody treatments for multiple sclerosis.

Curr Neurol Neurosci Rep. 2008 Sep;8(5):419-26. doi: 10.1007/s11910-008-0065-3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

FDA advisers endorse natalizumab for Crohn's disease.

Am J Health Syst Pharm. 2007 Sep 15;64(18):1886, 1888, 1890. doi: 10.2146/news070080.

The comeback kid: TYSABRI now FDA approved for Crohn disease.

J Clin Invest. 2008 Mar;118(3):825-6. doi: 10.1172/JCI35179.

Natalizumab (Tysabri) for Crohn's disease.

Med Lett Drugs Ther. 2008 May 5;50(1285):34-6.

Natalizumab for induction of remission in Crohn's disease.

Cochrane Database Syst Rev. 2006 Jul 19(3):CD006097. doi: 10.1002/14651858.CD006097.

Natalizumab for induction of remission in Crohn's disease.

Cochrane Database Syst Rev. 2007 Jan 24(1):CD006097. doi: 10.1002/14651858.CD006097.pub2.

TNF inhibitors for Crohn's disease: when, which, and for how long.

Med Lett Drugs Ther. 2013 Dec 23;55(1432):102-3.

Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab.

Expert Opin Biol Ther. 2003 Sep;3(6):995-1000. doi: 10.1517/14712598.3.6.995.

Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference.

Inflamm Bowel Dis. 1998 Nov;4(4):328-9. doi: 10.1002/ibd.3780040415.

Natalizumab induction and maintenance therapy for Crohn's disease.

N Engl J Med. 2005 Nov 3;353(18):1912-25. doi: 10.1056/NEJMoa043335.

Natalizumab for active Crohn's disease.

N Engl J Med. 2003 Jan 2;348(1):24-32. doi: 10.1056/NEJMoa020732.

引用本文的文献

Vedolizumab: Beyond Inflammatory Bowel Disease.

Med Princ Pract. 2025 Jun 19:1-13. doi: 10.1159/000547015.

Targeting integrin pathways: mechanisms and advances in therapy.

Signal Transduct Target Ther. 2023 Jan 2;8(1):1. doi: 10.1038/s41392-022-01259-6.

Monoclonal antibody treatments for multiple sclerosis.

Curr Treat Options Neurol. 2009 May;11(3):211-20. doi: 10.1007/s11940-009-0025-5.

Monoclonal antibody treatments for multiple sclerosis.

Curr Neurol Neurosci Rep. 2008 Sep;8(5):419-26. doi: 10.1007/s11910-008-0065-3.